Floatz logo

Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes

Refractory Chronic Lymphocytic Leukemia

Fred Hutchinson Cancer CenterCell therapyPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

212 Active assets in the Refractory Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Weill Medical College of Cornell University
Phase 2BBB
Fludarabine
Roswell Park Cancer Institute
Phase 3BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Hoffmann-La Roche
Phase 4BBB
CHLORAMBUCIL
Ascentage Pharma Group Inc.
Phase 4BBB
Apg-2575
Henan Cancer Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes is also rated in:

cytomegalovirus infectionDormant
CCC
Indicative ·
53 / 100
View asset →
hematopoietic and lymphoid cell neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →